What's New Research in Diabetes
The drive to discover new and innovative solutions for
managing diabetes is international. The Diabetes UK Professional Conference,
held in Glasgow in March 2016, presented many of these advances and
developments, including new insights into diabulimia; the role of mindfulness
in diabetes management; risk factors for Type 2 diabetes in the younger
generations; and new discoveries in glucose monitoring and management. Through
interviews conducted with the presenters of these topics, Dr. Nicola Davies
explores the latest innovations in diabetes research.
Dr. Steve Bain, clinical lead for the Diabetes Research
Network in Wales, is working on an oral medication for stabilizing glycemic
levels that is currently in the trial stages. The medication, semaglutide, is
an investigational glucagon-like peptide-1 analog that is showing promising
results in the treatment of Type 2 diabetes. One weekly dose of semaglutide
significantly improved glycemic control in trial participants compared with
previous treatments, outperforming even the most widely used Type 2 diabetes
treatment, metformin.
For the latest technology in glucose monitoring, Dr. Bain
recommends the Abbot Freestyle Libre, a flash glucose monitor that scans blood
glucose measurements rather than relying on the painful and inconvenient method
of frequent pinpricks. A sensor is affixed to the skin, and a person needs only
wave the glucose reader within an inch and half of it to check blood sugar
levels. The device works through clothing and is water resistant, so the wearer
can swim, exercise, shower, or bathe. Bain says, “If the Abbott Freestyle Libre
device is available on prescription, it will become hugely popular.”
Dr. Brian Frier, honorary professor of diabetes at the
University of Edinburgh, also sees tremendous potential in the Freestyle Libre.
He considers it a more practical alternative to the trendy continuous glucose
monitoring (CGM) systems on the market. According to Frier, the Freestyle Libre
“relies on flash glucose testing at five-minute intervals. This is not the same
as CGM, but enables frequent testing of glucose so that the individual can see
the direction of travel of their glucose, such as whether it is stable, rising
or falling. The reports I have heard from patients is that they find this
method of monitoring to be very valuable.”
This new form of glucose monitoring provides greater
flexibility in lifestyles and glycemic targets. Frier notes, “Guidelines
[regarding individualizing targets for people with diabetes] have now abandoned
the previous impractical (and frankly dangerous) blanket approach to glycemic targets
in that everyone was to aim for very strict control, irrespective of age and
co-existing medical disorders. Sensible targets are now being advocated for
frail elderly people, very young children with Type 1 diabetes, and other
groups, while promoting very strict control where this is essential, such as in
pregnancy.
Looking to the future
Researchers continue to develop new treatments to assist the
almost 620 million people worldwide with various forms of diabetes. The
Diabetes UK Professional Conference kept attendees abreast of current
developments in the field. The sessions were invaluable for increasing
awareness regarding troubling trends in the diabetes community or developing
new methods or technologies to help people with diabetes manage and monitor
their condition. The insights provided predict a future with greater public
awareness of the risk of unhealthy lifestyles, a higher standard of care that
can be provided by practitioners and a higher quality of life for people with
diabetes.
0 comments:
Post a Comment